Global In-Vitro Diagnostics Market

In-Vitro Diagnostics Market Size, Share, Growth Analysis, By Product Type(Instruments & Reagents, Software, and Services), By Specimen(Blood, CSF, Urine, Blood Fluid), By Technology(Immunoassays, Clinical Chemistry, Molecular diagnostics, Hematology), By Test Type(Laboratory Tests, and Point-Of-Care Tests), By Vertical(Hospitals & Clinics, Clinical Laboratories, Blood Banks, Home Care Settings), By Application(Infectious Diseases, Diabetics, Oncology, Nephrology), By Product Type(), By Specimen(), By Technology(), By Test Type(), By Vertical(), By Application(), By Region - Industry Forecast 2024-2031


Report ID: SQSG35G2015 | Region: Global | Published Date: June, 2024
Pages: 157 | Tables: 124 | Figures: 77

In-Vitro Diagnostics Market News

 

  • A new in vitro serological ELISA kit was launched recently in August 2024. InBios International was behind this new launch that was aimed at presumptive clinical laboratory diagnosis of Strongyloides infection.  

  • In June 2024, Cupid Limited announced the launch of its extensive distribution network in India for rapid in-vitro diagnostics kits. This move helped Cupid secure and strengthen its presence in the Indian diagnostics market.  

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The global in-vitro diagnostics market size was valued at USD 83.50 Billion in 2022 and is poised to grow from USD 87.93 Billion in 2023 to USD 132.90 Billion by 2031, growing at a CAGR of 5.3% during the forecast period (2024-2031). 

Investing in the research and development of advanced in-vitro diagnostics solutions will be a top priority for all market players. Increasing affordability of in-vitro diagnostics tests should also be a key focus for in-vitro diagnostics providers. Launching new in-vitro diagnostics products and tests will help companies stay competitive and stand out in the global market. Providing favorable reimbursement for in-vitro diagnostics will also be a crucial aspect for business expandion in the long run.   'Roche Diagnostics (Switzerland)  ', 'Danaher Corporation (U.S.)  ', 'Abbott Laboratories (U.S.)  ', 'Becton, Dickinson and Company (U.S.)  ', 'Bio-Rad Laboratories, Inc. (U.S.)  ', 'QIAGEN N.V. (Netherlands)  ', 'Quidel Corporation (U.S.)  ', 'Siemens Healthineers (Germany)  ', 'Sysmex Corporation (Japan)  ', 'Thermo Fisher Scientific, Inc (U.S.)  ', 'bioMérieux SA (France)  ', 'Agilent Technologies, Inc. (U.S.)  ', 'DiaSorin S.p.A (Italy)  ', 'Illumina, Inc. (U.S.)  ', 'Hologic, Inc. (U.S.)  ', 'Devyser PerkinElmer Inc. (U.S.)  ', 'Chembio Diagnostics, Inc. (U.S.)  ', 'Surmodics, Inc. (U.S.)  ', 'Menarini Silicon Biosystems (Italy)  ', 'SpeeDx Pty. Ltd. (Australia) '

The presence of developed healthcare infrastructure and key diagnostics providers allows North America to hold a dominant market share. Growing investments in R&D of novel diagnostics and the rising popularity of homecare in this region are also expected to boost sales of in-vitro diagnostics products in the future. Favorable regulatory environment and rising adoption of advanced diagnostics technologies are making the United States a key market for in-vitro diagnostics companies operating in North America.  

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global In-Vitro Diagnostics Market

Report ID: SQSG35G2015

$5,300
BUY NOW GET FREE SAMPLE